



Modular Program Report

The following report(s) provides findings from an FDA-initiated query using its Mini-Sentinel pilot. While Mini-Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Mini-Sentinel, and seeking to better understand the capabilities of the Mini-Sentinel pilot.

Data obtained through Mini-Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from the Mini-Sentinel pilot in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Mini-Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Mini-Sentinel Operations Center for assistance at info@mini-sentinel.org.

Overview

Request Description

These results were generated using 12 runs of the Mini-Sentinel Modular Program #3 to investigate the use of duloxetine, milnacipran, and pregabalin among enrollees with a pre-existing diagnosis of myalgia or myositis (ICD-9-CM code 729.1). The program was run six times for the three drug products separately and six times for the drug products grouped as one class: (1) once for the entire time period of January 1, 2006 to December 31, 2010, and (2) once for each individual year 2006-2010. The query was run against the Mini-Sentinel Distributed Database and distributed on February 27, 2012. **All counts of users, dispensings, and total days supplied were generated among those previously diagnosed with myalgia and myositis.**

The lookup period for myalgia and myositis was set to 90 days. The maximum allowable treatment gap was set to 14 days. The minimum episode duration, and minimum episode days supplied were set to zero. The drug washout period was set to zero to estimate prevalent use. The program data range was January 1, 2006 to December 31, 2010 and the care setting was restricted to ambulatory care visits (AV) only. The output was stratified by age group (0-17, 18-64, 65+) and sex.

Please review the Specifications page for request details.

Request ID Specifications

MSY3_MPR4

Program parameter inputs and scenarios

Table 1

Table of total number of users, total number of dispensings, and total days supplied of duloxetine, milnacipran, and pregabalin for years 2006-2010, yearly and in aggregate. The percent of users/dispensings/days supplied contributed by each drug product is presented as well.

Figures 1a, 1b, and 1c

Figures of total number of users, total dispensings, and total days supplied for each product separately and as one drug class for years 2006-2010, by drug and time period.

Table 2

Table of total number of users, total number of dispensings, and total days supplied of duloxetine, milnacipran, and pregabalin for years 2006-2010, yearly and in aggregate by age. The percent of users/dispensings/days supplied contributed by each drug product is presented as well.

Table 3

Table of total number of users, total number of dispensings, and total days supplied of duloxetine, milnacipran, and pregabalin for years 2006-2010, yearly and in aggregate by sex. The percent of users/dispensings/days supplied contributed by each drug product is presented as well.

Table 4

Rate of Drug Use (Duloxetine, Milnacipran, and Pregabalin) for Years 2006-2010, by Drug and Year.

Overview (Con't)

Notes:

A user will only be counted once in results where the drug products are grouped as one class. However, a user may be counted in more than one drug product category when results are shown for the separate drug products. This is why the sums of counts and percentages for the separate drug products may be greater than the counts and 100% for the drug products grouped as one class.

Please contact the Mini-Sentinel Operations Center (MSOC_Requests@harvardpilgrim.org) for questions and to provide comments/suggestions for future enhancements to this document.

Modular Program Specifications

Modular Program #3 was used to investigate the use of duloxetine, milnacipran, and pregabalin among enrollees with a pre-existing diagnosis of myalgia or myositis (ICD-9-CM code 729.1). The program was run six times for the three drug products separately and six times for the drug products grouped as one class: (1) once for the entire time period of January 1, 2006 to December 31, 2010, and (2) once for each individual year 2006-2010. The enrollment gap was set to 45 days, and age groups examined were 0-17, 18-64, and 65+ years. In total, there were 24 scenarios that differed by incident exposure and query period.

Scenario	Drug/Exposure Criteria							Pre-Existing Condition Criteria				
	Query Start Date	Query End Date	Incident Exposure	Min Episode			Episode Gap (days)	Pre-Existing Condition	Care Setting	Principal Dx?	Lookback Type*	Lookback Period (days)
				Washout (days)	Duration (days)	Min Days Supplied						
1	1/1/2006	12/31/2010	Duloxetine	0	0	0	14	Myalgia	AV	No	Fixed	90
2	1/1/2006	12/31/2006	Duloxetine	0	0	0	14	Myalgia	AV	No	Fixed	90
3	1/1/2007	12/31/2007	Duloxetine	0	0	0	14	Myalgia	AV	No	Fixed	90
4	1/1/2008	12/31/2008	Duloxetine	0	0	0	14	Myalgia	AV	No	Fixed	90
5	1/1/2009	12/31/2009	Duloxetine	0	0	0	14	Myalgia	AV	No	Fixed	90
6	1/1/2010	12/31/2010	Duloxetine	0	0	0	14	Myalgia	AV	No	Fixed	90
7	1/1/2006	12/31/2010	Milnacipran	0	0	0	14	Myalgia	AV	No	Fixed	90
8	1/1/2006	12/31/2006	Milnacipran	0	0	0	14	Myalgia	AV	No	Fixed	90
9	1/1/2007	12/31/2007	Milnacipran	0	0	0	14	Myalgia	AV	No	Fixed	90
10	1/1/2008	12/31/2008	Milnacipran	0	0	0	14	Myalgia	AV	No	Fixed	90
11	1/1/2009	12/31/2009	Milnacipran	0	0	0	14	Myalgia	AV	No	Fixed	90
12	1/1/2010	12/31/2010	Milnacipran	0	0	0	14	Myalgia	AV	No	Fixed	90
13	1/1/2006	12/31/2010	Pregabalin	0	0	0	14	Myalgia	AV	No	Fixed	90
14	1/1/2006	12/31/2006	Pregabalin	0	0	0	14	Myalgia	AV	No	Fixed	90
15	1/1/2007	12/31/2007	Pregabalin	0	0	0	14	Myalgia	AV	No	Fixed	90
16	1/1/2008	12/31/2008	Pregabalin	0	0	0	14	Myalgia	AV	No	Fixed	90
17	1/1/2009	12/31/2009	Pregabalin	0	0	0	14	Myalgia	AV	No	Fixed	90
18	1/1/2010	12/31/2010	Pregabalin	0	0	0	14	Myalgia	AV	No	Fixed	90
19	1/1/2006	12/31/2010	Any Drug**	0	0	0	14	Myalgia	AV	No	Fixed	90
20	1/1/2006	12/31/2006	Any Drug	0	0	0	14	Myalgia	AV	No	Fixed	90
21	1/1/2007	12/31/2007	Any Drug	0	0	0	14	Myalgia	AV	No	Fixed	90
22	1/1/2008	12/31/2008	Any Drug	0	0	0	14	Myalgia	AV	No	Fixed	90
23	1/1/2009	12/31/2009	Any Drug	0	0	0	14	Myalgia	AV	No	Fixed	90
24	1/1/2010	12/31/2010	Any Drug	0	0	0	14	Myalgia	AV	No	Fixed	90

*A "fixed" lookback type for the pre-existing condition will look for the pre-existing condition during a specified number of days (lookback period) prior to the index date.

**The "Any Drug" group defines incident exposure as exposure to any of the following drugs: Duloxetine, Milnacipran, or Pregabalin.


Table 1. Summary of Drug Use (Duloxetine, Milnacipran, and Pregabalin) for Years 2006-2010, by Drug and Time Period

	ANY DRUG*	DULOXETINE	MILNACIPRAN	PREGABALIN
	N (%)	N (%)	N (%)	N (%)
Users				
2006	11,090 (100.0%)	8,395 (75.7%)	0 (0.0%)	3,786 (34.1%)
2007	16,540 (100.0%)	10,400 (62.9%)	0 (0.0%)	8,605 (52.0%)
2008	27,980 (100.0%)	15,216 (54.4%)	0 (0.0%)	17,966 (64.2%)
2009	35,114 (100.0%)	21,816 (62.1%)	4,858 (13.8%)	16,516 (47.0%)
2010	43,794 (100.0%)	25,393 (58.0%)	9,177 (21.0%)	18,100 (41.3%)
2006-2010	76,658 (100.0%)	47,769 (62.3%)	12,345 (16.1%)	42,319 (55.2%)
Dispensings				
2006	67,929 (100.0%)	50,683 (74.6%)	0 (0.0%)	15,070 (22.2%)
2007	100,812 (100.0%)	64,025 (63.5%)	0 (0.0%)	35,903 (35.6%)
2008	163,828 (100.0%)	90,298 (55.1%)	0 (0.0%)	74,627 (45.6%)
2009	191,680 (100.0%)	114,899 (59.9%)	16,080 (8.4%)	68,644 (35.8%)
2010	210,957 (100.0%)	117,003 (55.5%)	28,264 (13.4%)	70,097 (33.2%)
2006-2010	333,280 (100.0%)	217,789 (65.3%)	36,611 (11.0%)	144,778 (43.4%)
Days Supplied				
2006	2,271,524 (100.0%)	1,753,646 (77.2%)	0 (0.0%)	455,911 (20.1%)
2007	3,427,943 (100.0%)	2,266,073 (66.1%)	0 (0.0%)	1,131,149 (33.0%)
2008	5,500,563 (100.0%)	3,153,545 (57.3%)	0 (0.0%)	2,377,674 (43.2%)
2009	6,515,743 (100.0%)	4,036,599 (62.0%)	515,987 (7.9%)	2,243,769 (34.4%)
2010	7,380,264 (100.0%)	4,215,289 (57.1%)	940,634 (12.7%)	2,380,378 (32.3%)
2006-2010	11,106,540 (100.0%)	7,512,352 (67.6%)	1,189,316 (10.7%)	4,562,492 (41.1%)

Note: Individual drug product percentages may sum to more than 100 - see Notes section in Overview sheet.


*The "Any Drug" group defines incident exposure as exposure to any of the following drugs: Duloxetine, Milnacipran, or Pregabalin.

Figure 1a. Total Number of Users for each Product Separately and as One Drug Class for Years 2006-2010, by Drug and Time Period




*The "Any Drug" group defines incident exposure as exposure to any of the following drugs: Duloxetine, Milnacipran, or Pregabalin.

Figure 1b. Total Number of Dispensings for each Product Separately and as One Drug Class for Years 2006-2010, by Drug and Time Period



*The "Any Drug" group defines incident exposure as exposure to any of the following drugs: Duloxetine, Milnacipran, or Pregabalin.

Figure 1c. Total Number of Days Supplied for each Product Separately and as One Drug Class for Years 2006-2010, by Drug and Time Period



*The "Any Drug" group defines incident exposure as exposure to any of the following drugs: Duloxetine, Milnacipran, or Pregabalin.

Table 2. Summary of Drug Use (Duloxetine, Milnacipran, and Pregabalin) for Years 2006-2010, by Drug, Time Period, and Age Group

	ANY DRUG*	DULOXETINE	MILNACIPRAN	PREGABALIN
	N	N (%)	N (%)	N (%)
2006				
Total				
<i>Unique Users</i>	11,090	8,395 (75.7%)	0 (0.0%)	3,786 (45.1%)
<i>Dispensings</i>	67,929	50,683 (74.6%)	0 (0.0%)	15,070 (29.7%)
<i>Total Days Supplied</i>	2,271,524	1,753,646 (77.2%)	0 (0.0%)	455,911 (26.0%)
Age Group				
0 to 17				
Unique Users	52	40 (76.9%)	0 (0.0%)	16 (40.0%)
Dispensings	180	140 (77.8%)	0 (0.0%)	39 (27.9%)
Total Days Supplied	4,772	3,652 (76.5%)	0 (0.0%)	1,120 (30.7%)
18 to 64				
Unique Users	10,220	7,848 (76.8%)	0 (0.0%)	3,382 (43.1%)
Dispensings	63,319	47,574 (75.1%)	0 (0.0%)	13,753 (28.9%)
Total Days Supplied	2,112,531	1,639,863 (77.6%)	0 (0.0%)	414,843 (25.3%)
65+				
Unique Users	818	507 (62.0%)	0 (0.0%)	388 (76.5%)
Dispensings	4,430	2,969 (67.0%)	0 (0.0%)	1,278 (43.0%)
Total Days Supplied	154,221	110,131 (71.4%)	0 (0.0%)	39,948 (36.3%)
2007				
Total				
<i>Unique Users</i>	16,540	10,400 (62.9%)	0 (0.0%)	8,605 (52.0%)
<i>Dispensings</i>	100,812	64,025 (63.5%)	0 (0.0%)	35,903 (35.6%)
<i>Total Days Supplied</i>	3,427,943	2,266,073 (66.1%)	0 (0.0%)	1,131,149 (33.0%)
Age Group				
0 to 17				
Unique Users	70	43 (61.4%)	0 (0.0%)	44 (62.9%)
Dispensings	273	181 (66.3%)	0 (0.0%)	151 (55.3%)
Total Days Supplied	9,120	5,741 (62.9%)	0 (0.0%)	5,036 (55.2%)
18 to 64				
Unique Users	14,921	9,545 (64.0%)	0 (0.0%)	7,644 (51.2%)
Dispensings	92,578	58,807 (63.5%)	0 (0.0%)	32,733 (35.4%)
Total Days Supplied	3,128,213	2,069,325 (66.2%)	0 (0.0%)	1,022,870 (32.7%)
65+				
Unique Users	1,549	812 (52.4%)	0 (0.0%)	917 (59.2%)
Dispensings	7,961	5,037 (63.3%)	0 (0.0%)	3,019 (37.9%)
Total Days Supplied	290,610	191,007 (65.7%)	0 (0.0%)	103,243 (35.5%)
2008				
Total				
<i>Unique Users</i>	27,980	15,216 (54.4%)	0 (0.0%)	17,966 (64.2%)
<i>Dispensings</i>	163,828	90,298 (55.1%)	0 (0.0%)	74,627 (45.6%)
<i>Total Days Supplied</i>	5,500,563	3,153,545 (57.3%)	0 (0.0%)	2,377,674 (43.2%)
Age Group				
0 to 17				
Unique Users	103	59 (57.3%)	0 (0.0%)	56 (54.4%)
Dispensings	600	343 (57.2%)	0 (0.0%)	223 (37.2%)
Total Days Supplied	19,008	10,174 (53.5%)	0 (0.0%)	7,390 (38.9%)
18 to 64				
Unique Users	23,998	13,338 (55.6%)	0 (0.0%)	15,276 (63.7%)
Dispensings	143,863	79,556 (55.3%)	0 (0.0%)	65,017 (45.2%)
Total Days Supplied	4,797,459	2,762,267 (57.6%)	0 (0.0%)	2,052,592 (42.8%)
65+				
Unique Users	3,879	1,819 (46.9%)	0 (0.0%)	2,634 (67.9%)
Dispensings	19,365	10,399 (53.7%)	0 (0.0%)	9,387 (48.5%)
Total Days Supplied	684,096	381,104 (55.7%)	0 (0.0%)	317,692 (46.4%)

Note: Individual drug product percentages may sum to more than 100 - see Notes section in Overview sheet.

*The "Any Drug" group defines incident exposure as exposure to any of the following drugs: Duloxetine, Milnacipran, or Pregabalin.

Table 2. Summary of Drug Use (Duloxetine, Milnacipran, and Pregabalin) for Years 2006-2010, by Drug, Time Period, and Age Group

	ANY DRUG*	DULOXETINE	MILNACIPRAN	PREGABALIN
	N	N (%)	N (%)	N (%)
2009				
Total				
<i>Unique Users</i>	35,114	21,816 (62.1%)	4,858 (13.8%)	16,516 (47.0%)
<i>Dispensings</i>	191,680	114,899 (59.9%)	16,080 (8.4%)	68,644 (35.8%)
<i>Total Days Supplied</i>	6,515,743	4,036,599 (62.0%)	515,987 (7.9%)	2,243,769 (34.4%)
Age Group				
0 to 17				
Unique Users	162	98 (60.5%)	9 (5.6%)	82 (50.6%)
Dispensings	653	334 (51.1%)	20 (3.1%)	305 (46.7%)
Total Days Supplied	20,291	10,012 (49.3%)	508 (2.5%)	9,384 (46.2%)
18 to 64				
Unique Users	30,984	19,218 (62.0%)	4,588 (14.8%)	14,582 (47.1%)
Dispensings	169,665	101,510 (59.8%)	15,188 (9.0%)	60,595 (35.7%)
Total Days Supplied	5,700,354	3,526,434 (61.9%)	483,545 (8.5%)	1,958,037 (34.3%)
65+				
Unique Users	3,968	2,500 (63.0%)	261 (6.6%)	1,852 (46.7%)
Dispensings	21,362	13,055 (61.1%)	872 (4.1%)	7,744 (36.3%)
Total Days Supplied	795,098	500,153 (62.9%)	31,934 (4.0%)	276,348 (34.8%)
2010				
Total				
<i>Unique Users</i>	43,794	25,393 (58.0%)	9,177 (36.1%)	18,100 (71.3%)
<i>Dispensings</i>	210,957	117,003 (55.5%)	28,264 (24.2%)	70,097 (59.9%)
<i>Total Days Supplied</i>	7,380,264	4,215,289 (57.1%)	940,634 (22.3%)	2,380,378 (56.5%)
Age Group				
0 to 17				
Unique Users	160	101 (63.1%)	12 (11.9%)	75 (74.3%)
Dispensings	623	343 (55.1%)	22 (6.4%)	261 (76.1%)
Total Days Supplied	20,492	11,284 (55.1%)	645 (5.7%)	8,743 (77.5%)
18 to 64				
Unique Users	38,596	22,339 (57.9%)	8,288 (37.1%)	16,032 (71.8%)
Dispensings	186,955	103,553 (55.4%)	25,608 (24.7%)	61,849 (59.7%)
Total Days Supplied	6,458,238	3,686,519 (57.1%)	844,165 (22.9%)	2,072,010 (56.2%)
65+				
Unique Users	5,038	2,953 (58.6%)	877 (29.7%)	1,993 (67.5%)
Dispensings	23,379	13,107 (56.1%)	2,634 (20.1%)	7,987 (60.9%)
Total Days Supplied	901,534	517,486 (57.4%)	95,824 (18.5%)	299,625 (57.9%)
2006-2010				
Total				
<i>Unique Users</i>	76,658	47,769 (62.3%)	12,345 (16.1%)	42,319 (55.2%)
<i>Dispensings</i>	333,280	217,789 (65.3%)	36,611 (11.0%)	144,778 (43.4%)
<i>Total Days Supplied</i>	11,106,540	7,512,352 (67.6%)	1,189,316 (10.7%)	4,562,492 (41.1%)
Age Group				
0 to 17				
Unique Users	440	285 (64.8%)	20 (4.5%)	223 (50.7%)
Dispensings	1,607	1,015 (63.2%)	40 (2.5%)	703 (43.7%)
Total Days Supplied	49,245	30,399 (61.7%)	1,093 (2.2%)	22,036 (44.7%)
18 to 64				
Unique Users	67,875	42,625 (62.8%)	11,302 (16.7%)	37,250 (54.9%)
Dispensings	299,735	196,034 (65.4%)	33,558 (11.2%)	128,982 (43.0%)
Total Days Supplied	9,906,761	6,711,508 (67.7%)	1,079,723 (10.9%)	4,027,905 (40.7%)
65+				
Unique Users	8,343	4,859 (58.2%)	1,023 (12.3%)	4,846 (58.1%)
Dispensings	31,938	20,740 (64.9%)	3,013 (9.4%)	15,093 (47.3%)
Total Days Supplied	1,150,534	770,445 (67.0%)	108,500 (9.4%)	512,551 (44.5%)

Note: Individual drug product percentages may sum to more than 100 - see Notes section in Overview sheet.

*The "Any Drug" group defines incident exposure as exposure to any of the following drugs: Duloxetine, Milnacipran, or Pregabalin.

Table 3. Summary of Drug Use (Duloxetine, Milnacipran, and Pregabalin) for Years 2006-2010, by Drug, Time Period, and Sex

	ANY DRUG *	DULOXETINE	MILNACIPRAN	PREGABALIN
	N	N (%)	N (%)	N (%)
2006				
Sex				
Female				
Unique Users	9,460	7,341 (77.6%)	0 (0.0%)	3,064 (32.4%)
Dispensings	59,487	45,313 (76.2%)	0 (0.0%)	12,214 (20.5%)
Total Days Supplied	2,002,972	1,577,149 (78.7%)	0 (0.0%)	369,898 (18.5%)
Male				
Unique Users	1,621	1,047 (64.6%)	0 (0.0%)	719 (44.4%)
Dispensings	8,383	5,331 (63.6%)	0 (0.0%)	2,841 (33.9%)
Total Days Supplied	266,194	174,712 (65.6%)	0 (0.0%)	85,590 (32.2%)
Unknown				
Unique Users	9	7 (77.8%)	0 (0.0%)	3 (33.3%)
Dispensings	59	39 (66.1%)	0 (0.0%)	15 (25.4%)
Total Days Supplied	2,358	1,785 (75.7%)	0 (0.0%)	423 (17.9%)
2007				
Sex				
Female				
Unique Users	14,251	9,075 (63.7%)	0 (0.0%)	7,380 (51.8%)
Dispensings	88,007	56,609 (64.3%)	0 (0.0%)	30,770 (35.0%)
Total Days Supplied	3,003,480	2,013,374 (67.0%)	0 (0.0%)	967,550 (32.2%)
Male				
Unique Users	2,280	1,317 (57.8%)	0 (0.0%)	1,220 (53.5%)
Dispensings	12,748	7,334 (57.5%)	0 (0.0%)	5,119 (40.2%)
Total Days Supplied	422,093	249,619 (59.1%)	0 (0.0%)	163,269 (38.7%)
Unknown				
Unique Users	9	8 (88.9%)	0 (0.0%)	5 (55.6%)
Dispensings	57	82 (143.9%)	0 (0.0%)	14 (24.6%)
Total Days Supplied	2,370	3,080 (130.0%)	0 (0.0%)	330 (13.9%)
2008				
Sex				
Female				
Unique Users	24,566	13,432 (54.7%)	0 (0.0%)	15,810 (64.4%)
Dispensings	144,728	80,261 (55.5%)	0 (0.0%)	65,236 (45.1%)
Total Days Supplied	4,862,005	2,808,343 (57.8%)	0 (0.0%)	2,076,583 (42.7%)
Male				
Unique Users	3,387	1,769 (52.2%)	0 (0.0%)	2,140 (63.2%)
Dispensings	19,004	9,970 (52.5%)	0 (0.0%)	9,349 (49.2%)
Total Days Supplied	635,813	343,245 (54.0%)	0 (0.0%)	300,063 (47.2%)
Unknown				
Unique Users	27	15 (55.6%)	0 (0.0%)	16 (59.3%)
Dispensings	96	67 (69.8%)	0 (0.0%)	42 (43.8%)
Total Days Supplied	2,745	1,957 (71.3%)	0 (0.0%)	1,028 (37.4%)
2009				
Sex				
Female				
Unique Users	30,697	19,237 (62.7%)	4,466 (14.5%)	14,266 (46.5%)
Dispensings	169,277	102,299 (60.4%)	14,978 (8.8%)	59,146 (34.9%)
Total Days Supplied	5,767,613	3,604,455 (62.5%)	480,721 (8.3%)	1,932,766 (33.5%)
Male				
Unique Users	4,381	2,561 (58.5%)	383 (8.7%)	2,234 (51.0%)
Dispensings	22,262	12,490 (56.1%)	1,089 (4.9%)	9,467 (42.5%)
Total Days Supplied	744,304	429,017 (57.6%)	35,088 (4.7%)	310,152 (41.7%)
Unknown				
Unique Users	36	18 (50.0%)	9 (25.0%)	16 (44.4%)
Dispensings	141	110 (78.0%)	13 (9.2%)	31 (22.0%)
Total Days Supplied	3,826	3,127 (81.7%)	178 (4.7%)	851 (22.2%)

Note: Individual drug product percentages may sum to more than 100 - see Notes section in Overview sheet.

*The "Any Drug" group defines incident exposure as exposure to any of the following drugs: Duloxetine, Milnacipran, or Pregabalin.

Table 3. Summary of Drug Use (Duloxetine, Milnacipran, and Pregabalin) for Years 2006-2010, by Drug, Time Period, and Sex

	ANY DRUG *	DULOXETINE	MILNACIPRAN	PREGABALIN
	N	N (%)	N (%)	N (%)
2010				
Sex				
Female				
Unique Users	38,313	22,384 (58.4%)	8,464 (37.8%)	15,463 (69.1%)
Dispensings	185,167	103,654 (56.0%)	26,200 (25.3%)	59,830 (57.7%)
Total Days Supplied	6,496,426	3,746,415 (57.7%)	872,956 (23.3%)	2,037,950 (54.4%)
Male				
Unique Users	5,448	2,989 (54.9%)	702 (23.5%)	2,624 (87.8%)
Dispensings	25,635	13,268 (51.8%)	2,017 (15.2%)	10,223 (77.1%)
Total Days Supplied	878,532	466,072 (53.1%)	65,984 (14.2%)	341,048 (73.2%)
Unknown				
Unique Users	33	20 (60.6%)	11 (55.0%)	13 (65.0%)
Dispensings	155	81 (52.3%)	47 (58.0%)	44 (54.3%)
Total Days Supplied	5,306	2,802 (52.8%)	1,694 (60.5%)	1,380 (49.3%)
2006-2010				
Sex				
Female				
Unique Users	66,053	41,579 (62.9%)	11,364 (17.2%)	36,327 (55.0%)
Dispensings	290,691	192,040 (66.1%)	33,999 (11.7%)	124,287 (42.8%)
Total Days Supplied	9,726,245	6,656,023 (68.4%)	1,104,884 (11.4%)	3,919,914 (40.3%)
Male				
Unique Users	10,535	6,144 (58.3%)	962 (9.1%)	5,956 (56.5%)
Dispensings	42,327	25,523 (60.3%)	2,564 (6.1%)	20,394 (48.2%)
Total Days Supplied	1,372,060	849,008 (61.9%)	82,920 (6.0%)	640,036 (46.6%)
Unknown				
Unique Users	70	46 (65.7%)	19 (27.1%)	36 (51.4%)
Dispensings	262	226 (86.3%)	48 (18.3%)	97 (37.0%)
Total Days Supplied	8,235	7,321 (88.9%)	1,512 (18.4%)	2,542 (30.9%)

Note: Individual drug product percentages may sum to more than 100 - see Notes section in Overview sheet.

*The "Any Drug" group defines incident exposure as exposure to any of the following drugs: Duloxetine, Milnacipran, or Pregabalin.

Table 4. Rate of Drug Use (Duloxetine, Milnacipran, and Pregabalin) for Years 2006-2010, by Drug and Year

	ANY DRUG*			DULOXETINE			MILNACIPRAN			PREGABALIN		
	Users	Members	Rate of Use	Users	Members	Rate of Use	Users	Members	Rate of Use	Users	Members	Rate of Use
2006	11,090	30,811,115	36.0	8,395	30,811,115	27.2	0	30,811,115	0.0	3,786	30,811,115	12.3
2007	16,540	34,303,646	48.2	10,400	34,303,646	30.3	0	34,303,646	0.0	8,605	34,303,646	25.1
2008	27,980	47,086,296	59.4	15,216	47,086,296	32.3	0	47,086,296	0.0	17,966	47,086,296	38.2
2009	35,114	45,103,516	77.9	21,816	45,103,516	48.4	4,858	45,103,516	10.8	16,516	45,103,516	36.6
2010	43,794	43,790,907	100.0	25,393	43,790,907	58.0	9,177	43,790,907	21.0	18,100	43,790,907	41.3

Note: Individual drug product percentages may sum to more than 100 - see Notes section in Overview sheet.

*The "Any Drug" group defines incident exposure as exposure to any of the following drugs: Duloxetine, Milnacipran, or Pregabalin.